Alembic Pharma hits 52-week high on final USFDA approval for Deferasirox tablets
The company now has a total of 122 ANDA approvals (109 final approvals and 13 tentative approvals) from USFDA.16-06-2020
16-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Deferasirox Tablets, 180 mg. Please find enclosed herewith our press release. We request you to kindly take the same on record.16-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Disclosure Of Related Party Transactions Pursuant To Regulation 23(9) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosures Requirements) Regulations, 2015 ('Listing Regulations, 2015')
Pursuant to Regulation 23(9) of the Listing Regulations, 2015, we enclose herewith Disclosure of Related Party Transactions, on a consolidated basis, for the period ended 31st March, 2020. We request you to kindly take the same on record.11-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Submission Of Notice Of 10Th Annual General Meeting Of The Company
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith Notice of 10th Annual General Meeting of the Members of the Company scheduled to be held on Wednesday, the 22nd July, 2020 at 3:00 p.m. IST through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'). We request you to kindly take the same on record.11-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Reg. 34 (1) Annual Report
Pursuant to Regulation 34 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith a copy of the Annual Report of the Company for the financial year ended 31st March, 2020. We request you to kindly take the same on record.11-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of Notice of 10th Annual General Meeting of the Company to be held through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM'), published in English and vernacular language (Gujarati) newspaper on 8th June, 2020 in Economic Times English and Gujarati Edition. We request you to kindly take the same on record.08-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a copy of Notice w.r.t. transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) published in English and vernacular language (Gujarati) newspaper on 5th June, 2020 in Economic Times English and Gujarati Edition.05-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations, 2015')
Pursuant to Regulation 30 of the Listing Regulations, 2015, we enclose herewith a specimen of the reminder letter dated 3rd June, 2020 sent to the relevant shareholders for whom the dividend remains unpaid / unclaimed for seven or more consecutive years and whose shares are liable to be transferred to the Investor Education and Protection Fund ('IEPF') Authority as per Section 124(6) of the Companies Act, 2013 read with Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016, as amended from time to time. We request you to kindly take the same on record.04-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate
Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Compay ALEMBIC PHARMACEUTICALS LTD. 2 CIN L24230GJ2010PLC061123 3 Report filed for FY 2019-20 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 200 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 50 6 Actual borrowings done through debt securities in FY(c) 0 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} 50 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities The amount required to be borrowed by the Company through debt securities is not significant considering the overall borrowing of the Company Issue of Debt Securities for such an amount is administratively expensive and carries higher cost of funds as compared to other long term instruments Hence the Company did not borrow the said amount Name of the Company Secretary :-Charandeep Singh SalujaDesignation :-Company Secretary Name of the Chief Financial Officer :- R K Baheti Designation : -Director Finance and CFO Date: 31/01/202001-06-2020
ALEMBIC PHARMACEUTICALS LTD. - 533573 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayALEMBIC PHARMACEUTICALS LTD. 2CINL24230GJ2010PLC061123 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 699.46 4Highest Credit Rating during the previous FY AA+STABLE 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CRISIL LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. YES Name of the Company Secretary: Charandeep Singh Saluja Designation: Company Secretary EmailId: charandeep.singh@alembic.co.in Name of the Chief Financial Officer: R K Baheti Designation: Director Finance and CFO EmailId: rajkumar_baheti@alembic.co.in Date: 01/06/2020 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.01-06-2020